Study Identifies Causes of Death in Myeloproliferative Neoplasms
the Cancer Therapy Advisor take:
Patients with myeloproliferative neoplasms (MPNs) have a higher mortality rate compared to matched controls due to hematologic malignancy, infections and vascular events in younger patients, according to a Swedish population study published online ahead of print in the Journal of Clinical Oncology.
Researchers led by Malin Hultcrantz, MD, PhD, of the Karolinska University Hospital in Stockholm identified 9,285 patients with MPN from Swedish registries in order to assess cause of death in these patients when matched with controls.
They found that risk of death from cardiovascular and cerebrovascular disease in patients aged 70 to 79 were statistically significantly elevated compared to matched controls. In patients aged 50 to 59 at time of diagnosis, the ten-year probability of death from cardiovascular or cerebrovascular disease was higher.
They also found that survival in patients with MPN increased over time due to decreased probabilities of dying as a result of hematologic malignancies, infections and cardiovascular disease in younger patients.
“There is still a need for effective disease-modifying agents to improve patient outcomes,” the authors concluded.
Patients with MPNs have a higher mortality rate due to hematologic malignancy and vascular events.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
- Age-adjusted Comorbidity Predicts Survival in Laryngeal Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Role of miR-125a-5p Clarified in Bladder Cancer